Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now
Boehringer Ingelheim v. Sun Pharmaceutical — TRIJARDY XR Patent | PatSnap
Explore in Eureka
Case ID1:20-cv-01585
FiledNov 2020
ClosedJul 2025
Patent Litigation

Boehringer Ingelheim v. Sun Pharmaceutical: TRIJARDY XR Consent Judgment After 1,710 Days

Boehringer Ingelheim and its affiliates secured a consent judgment against Sun Pharmaceutical and Ohm Laboratories protecting TRIJARDY XR — a triple-combination diabetes tablet — across 11 asserted patents. The case ran for 1,710 days before resolving without a merits trial, with Sun enjoined from launching its generic ANDA products until all patent terms expire.

Resolution time
1710days
1,710 days — nearly 4.7 years, consistent with complex multi-patent ANDA litigation in D. Del.
Patents asserted
1
US7579449B2 and 10 further patents asserted — empagliflozin/linagliptin/metformin ER combination therapy
Outcome
Consent Judgment
All 11 patents held valid, enforceable, and infringed; Sun enjoined until patent expiry.
Cost ruling
No Costs Awarded
Dismissed without costs, disbursements, or attorneys’ fees to either party.
Published by PatSnap Insights Team · Verified by PatSnap Eureka Data
Case overview

An 11-patent ANDA blockade: how Boehringer locked out Sun’s TRIJARDY XR generics

Filed in November 2020 in the District of Delaware before Judge Colm F. Connolly, this ANDA infringement action is one of several consolidated cases in which Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH (collectively Boehringer) asserted a portfolio of eleven patents against Sun Pharmaceutical Industries, Inc. and Ohm Laboratories, Inc. The patents cover the branded product TRIJARDY XR — a once-daily extended-release tablet combining empagliflozin, linagliptin, and metformin hydrochloride for type 2 diabetes management, available in four dosage strengths.

The case closed on 30 July 2025 via a consent judgment — a negotiated court order that carries the force of a binding injunction without a full merits trial. The consent judgment declares all eleven patents (the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents) valid, enforceable, and infringed by Sun’s ANDA products. Sun is permanently enjoined from making, using, selling, or importing the generic ANDA products in the United States until each patent’s expiry, including any extensions or pediatric exclusivity. Importantly, the order preserves Sun’s right to challenge those same patents in relation to a different product not covered by the identified ANDAs.

The 1,710-day duration, spanning multiple consolidated actions across at least three separate case numbers, suggests protracted negotiation rather than imminent trial defeat — consent judgments in ANDA matters typically reflect a commercial settlement in which the generic party accepts a delayed market entry in exchange for certainty. The public record is silent on any agreed entry date or licensing arrangement, which is common when parties reach confidential co-settlement terms alongside the consent judgment. The no-costs provision is consistent with a negotiated resolution rather than a contested adjudication.

Case at a glance
Case no.1:20-cv-01585
CourtDelaware
JudgeColm F. Connolly
FiledNovember 23, 2020
ClosedJuly 30, 2025
Duration1710 days
OutcomeConsent Judgment
Verdict causeInfringement Action
BasisConsent Judgment
Prior Art Intelligence
See what prior art exists on this patent.
Eureka scans millions of patents and papers to surface prior art that may have invalidated these claims before costly litigation begins.
Check Prior Art
Case data sourced from PACER / Delaware District Court via PatSnap Eureka Litigation Intelligence Explore similar cases ↗
Case timeline

Filing to Consent Judgment in 1710 days

1,710 days — nearly 4.7 years, consistent with complex multi-patent ANDA litigation in D. Del.

Case timeline: Complaint filed NOV 23 2020, MAR–APR — 1710 days total Horizontal timeline showing the three key events in Boehringer-Ingelheim v Sun Pharmaceutical Industries, Inc. from filing to resolution. Source: PACER, Delaware District Court. NOV 23 2020 Complaint filed Pre-trial proceedings JUL 30 2025 Consent Judgment 1710 DAYS TOTAL
Dismissal terms

Consent judgment decoded: what Sun’s injunction means for both parties

Legal mechanism

Consent judgment: an injunction by agreement, not after trial

A consent judgment is a court-entered order reflecting the parties’ negotiated agreement. Unlike a trial verdict, it does not require the court to find facts independently — but once entered, it carries full injunctive force. Here, all eleven patents are declared valid and infringed by stipulation, and the court retains jurisdiction to enforce compliance. Sun retains only the narrow right to challenge those patents for non-ANDA products.

Binding injunction — no merits trial required
Patent holder outcome

Boehringer secures full portfolio protection through patent expiry

Boehringer obtained the strongest available ANDA outcome short of a trial win: a court order that formally validates all eleven patents and blocks Sun’s generic entry across all four TRIJARDY XR dosage strengths. The order explicitly captures any future patent term extensions, adjustments, and pediatric exclusivity — and reserves Boehringer’s right to seek further modifications if additional regulatory exclusivities arise. TRIJARDY XR’s commercial runway is legally secured.

Full exclusivity preserved
Generic challenger outcome

Sun accepts injunction but retains challenge rights for future products

Sun and Ohm Laboratories are enjoined from commercialising the specific ANDA products, but the consent judgment explicitly carves out Sun’s right to challenge the eleven patents in connection with any product beyond those identified ANDAs. This preservation clause is commercially significant: it suggests Sun may pursue a reformulated or distinct product pathway without the estoppel risk that a full trial loss would have created.

Future challenge rights preserved
Commercial implications

Multi-combination diabetes tablet IP: a high-stakes exclusivity model

TRIJARDY XR represents the growing trend of SGLT2-inhibitor combination therapies, where patent portfolios are layered across the active ingredients, formulation, and dosage regimen. Eleven patents across one product signals a defensive stacking strategy that substantially raises the cost and complexity of generic ANDA challenges. For competitors in the empagliflozin or linagliptin space, this outcome reinforces the durability of combination-product patent portfolios when litigated in Delaware.

Patent stacking — delayed generic entry
Legal analysis based on PACER docket records for case 1:20-cv-01585 and PatSnap Eureka litigation intelligence Search PatSnap Eureka ↗
Parties and representation

Full party and counsel information

RoleNameTypeDetail
PlaintiffBoehringer-IngelheimIndividualPharmaceutical innovator — holder of US7579449B2 and 10 further TRIJARDY XR patentsSearch in Eureka ↗
Co-PlaintiffBoehringer Ingelheim CorporationCompanySearch in Eureka ↗
Co-PlaintiffBoehringer Ingelheim International, GMBHCompanySearch in Eureka ↗
DefendantSun Pharmaceutical Industries, Inc.CompanyGeneric pharmaceutical manufacturer; filed ANDAs seeking to launch empagliflozin/linagliptin/metformin ER tabletsSearch in Eureka ↗
Co-DefendantSun Pharmaceutical Industries, Inc.CompanySearch in Eureka ↗
Co-DefendantOhm Laboratories, Inc.CompanySearch in Eureka ↗
Plaintiff counselBrian P. EganAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff counselJack B. BlumenfeldAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff counselMegan Elizabeth DellingerAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff law firmMorris, Nichols, Arsht & Tunnell LLPLaw FirmRepresenting Boehringer-IngelheimSearch in Eureka ↗
Defendant counselBryce A. CooperAttorneyCounsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗
Defendant counselCharles B. KleinAttorneyCounsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗
Defendant counselDavid A. BilsonAttorneyCounsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗
Defendant counselJohn C. Phillips , Jr.AttorneyCounsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗
Defendant law firmPhillips, McLaughlin & Hall PALaw FirmRepresenting Sun Pharmaceutical Industries, Inc.Search in Eureka ↗
Presiding judgeJudge Colm F. ConnollyJudgeDelaware District CourtSearch in Eureka ↗
Official verdict

Official order — verbatim text

“IT IS HEREBY ORDERED, ADJUDGED AND DECREED that: 1. This Court has jurisdiction over the subject matter of this action and has personal jurisdiction over the parties. 2. The ‘938, ‘957, ‘998 ‘637, ‘705, ‘O 16, ‘379, ‘172, ‘120, ‘449, and ‘323 patents are valid, enforceable, and infringed by the Sun ANDA Products. Notwithstanding the above, nothing precludes Sun from challenging the validity, enforceability, and/or infringement of the ‘938, ‘957, ‘998 ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents in connection with a product other than a product described in ANDA Nos. 212343, 212339, 214843, 215873, and 215529. 3. Unless specifically authorized or otherwise modified between the parties, Sun, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, importing or distributing the Sun ANDA Products in the United States, on its own or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with Sun or its Affiliates, through and until the expiration of the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents, including any patent term extension, patent term adjustment, or pediatric exclusivity. If Boehringer becomes entitled to any other regulatory exclusivities that are not referenced herein, Boehringer may apply to the Court for modification of the consent judgment to incorporate such specified exclusivity. 4. This Court retains jurisdiction to enforce performance under this Consent Judgment and any related agreement(s). The Parties agree that, in the event of violation of the terms of this Consent Judgment or any related agreement(s), this Court has personal jurisdiction over the parties and venue for an action to enforce performance under this Consent Judgment, including for a preliminary injunction against the breaching conduct and the Parties hereby waive any and all defenses based on lack of personal jurisdiction or venue. 5. The Complaints in Civil Action Nos. 18-1765-CFC (D. Del.) and 19- 1500-CFC (D. Del.), which have been consolidated with Civil Action No. 18-1689- CFC (D. Del.), and all remaining claims, counterclaims, or affirmative defenses in these actions, are dismissed without prejudice and without costs, disbursements, or attorneys’ fees to any party. 6. The Complaints in Civil Action Nos. 20-1153-CFC (D. Del.), 20-1585- CFC (D. Del.), and 21-356-CFC (D. Del.), which have been consolidated into Civil Action No. 20-1153-CFC (D. Del.), and all remaining claims, counterclaims, or affirmative defenses in these actions, are dismissed without prejudice and without costs, disbursements, or attorneys’ fees to any party. 7. The Complaints in Civil Action Nos. 21-1487-CFC (D. Del.) and 21- 1573-CFC (D. Del.), which have been consolidated with Civil Action No. 21-1485- CFC (D. Del.), and all remaining claims, counterclaims, or affirmative defenses in these actions, are dismissed without prejudice and without costs, disbursements, or attorneys’ fees to any party.”
Source: PACER Docket, Case 1:20-cv-01585, Delaware District Court

The consent judgment’s operative language — declaring all eleven patents ‘valid, enforceable, and infringed’ — creates a court-entered record that carries full preclusive effect against Sun’s ANDA products. The carve-out language (‘nothing precludes Sun from challenging… in connection with a product other than a product described in ANDA Nos. 212343, 212339, 214843, 215873, and 215529’) was deliberately drafted to limit Sun’s estoppel exposure, suggesting the parties negotiated the scope of preclusion as a material term. The no-costs provision and dismissal without prejudice of all remaining claims are characteristic of a commercially negotiated resolution.

PACER case 1:20-cv-01585 · Public docket record Explore in Eureka ↗
Patent at issue

US7579449B2 — empagliflozin/linagliptin/metformin combination therapy

Publication No.US7579449B2
Application No.US11/080150
Patent details
ProductTriple-combination oral diabetes tablet: SGLT2 inhibitor, DPP-4 inhibitor, and biguanide in ER form
Cited in actionNovember 23, 2020

US7579449B2 is one of eleven patents asserted by Boehringer Ingelheim in this ANDA litigation, all covering aspects of TRIJARDY XR — an extended-release oral tablet combining empagliflozin (an SGLT2 inhibitor), linagliptin (a DPP-4 inhibitor), and metformin hydrochloride (a biguanide). The combination addresses type 2 diabetes through three complementary mechanisms of action. Extended-release formulation patents in this class typically cover the dosage form, release profile, and specific weight ratios of active ingredients — each layer adding independent validity and enforceability.

From a competitive intelligence standpoint, the eleven-patent assertion against a single product signals that Boehringer has constructed a defensive patent thicket around TRIJARDY XR that mirrors its approach to other SGLT2-combination assets, including JARDIANCE and GLYXAMBI. Any company developing a fixed-dose combination incorporating empagliflozin or linagliptin — whether as a two-drug or three-drug regimen — should treat this portfolio as a primary FTO target. The consent judgment’s outcome strengthens the presumption of validity across all eleven patents and raises the evidentiary bar for any future challenger.

Patent data sourced from USPTO via PatSnap Eureka patent database Search patent records in Eureka ↗
Freedom to operate

Should you run an FTO against US7579449B2 and the TRIJARDY XR patent portfolio?

Any pharmaceutical or biotech company developing a fixed-dose combination tablet containing an SGLT2 inhibitor, a DPP-4 inhibitor, or metformin in extended-release form should treat this patent family as a priority FTO target. The consent judgment — which formally upholds all eleven patents as valid and enforceable — substantially strengthens their litigation posture. Generic manufacturers, authorised generic partners, and 505(b)(2) applicants developing competing diabetes combination products face elevated injunction risk if any of these claims read on their formulations.

PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their candidate formulations against the full Boehringer empagliflozin/linagliptin/metformin portfolio — including claim-level analysis, expiry timelines, and patent term extension status. By ingesting your formulation parameters, Eureka can flag claim overlap, identify design-around white space, and benchmark your risk profile against comparable ANDA outcomes in Delaware. Start your FTO analysis before IND filing to avoid costly late-stage reformulation.

PatSnap Eureka FTO Search

Run a freedom-to-operate analysis on US7579449B2 to assess your product’s exposure

Run FTO in Eureka →
Related litigation

Similar ANDA patent cases: SGLT2-inhibitor combination therapy litigation in D. Del.

Cases involving multi-patent ANDA assertions over SGLT2-inhibitor and DPP-4-inhibitor combination therapies in the Delaware District Court, including consent judgment outcomes.

🔍
Access 40+ similar cases in PatSnap Eureka
Boehringer-Ingelheim patent enforcement history, Delaware case history, Boehringer-Ingelheim’s full IP portfolio, and comparable case analysis
Boehringer v. Mylan (JARDIANCE)AstraZeneca SGLT2 ANDA casesD. Del. multi-patent ANDA outcomesDPP-4 inhibitor consent judgments
Unlock similar cases in Eureka →
Strategic implications

What this case signals for the SGLT2-inhibitor combination therapy IP landscape

Boehringer’s consent judgment outcome illustrates the commercial leverage that multi-patent ANDA portfolios generate against generic entrants in complex combination drug litigation.

Patent stacking in combination therapies raises the generic challenge bar significantly

Asserting eleven patents across a single combination product means a generic entrant must successfully invalidate or design around the entire portfolio — not just one claim. This case illustrates how innovators use layered IP coverage across active ingredients, formulation, and method-of-use claims to create near-impenetrable ANDA barriers in district court.

Consent judgments in ANDA cases often signal negotiated entry dates — watch for side agreements

When an ANDA case resolves via consent judgment with no costs awarded and a dismissal without prejudice, a confidential settlement authorising a future generic entry date is a common commercial structure. The public record here is silent on any such arrangement, but stakeholders monitoring the TRIJARDY XR generic market should track Sun’s ANDA status with FDA for any authorised generic signals.

🔒
Full strategic analysis in PatSnap Eureka
Unlock gated analysis on SGLT2-inhibitor ANDA strategy and Delaware District Court multi-patent consolidation tactics.
Sun’s preserved IP rightsAuthorised generic risk signalsD. Del. consolidation strategy
Unlock full analysis →
Analysis powered by PatSnap Eureka Litigation Intelligence Explore in Eureka ↗
Frequently asked questions

Boehringer-Ingelheim v Sun — key questions answered

Still have questions? PatSnap Eureka can answer them instantly from patent and litigation data. Ask Eureka ↗
PatSnap Eureka

Monitor TRIJARDY XR generic risk and SGLT2-combination FTO in one platform

PatSnap Eureka tracks all eleven TRIJARDY XR patents — including expiry, term extensions, and new ANDA activity — in real time. Run a freedom-to-operate analysis against your diabetes combination pipeline before the next filing deadline.

Ask anything about this case.
PatSnap Eureka searches patents and litigation data to answer instantly.
Powered by PatSnap Eureka
Link copied to clipboard

Related Litigation Cases

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.